Anika Therapeutics, Inc. ANIK
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 165.45% | -1,831.51% | 112.54% | 41.34% | 18.53% |
| Total Depreciation and Amortization | 6.97% | 6.75% | -6.06% | 10.73% | -20.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -53.82% | 92.16% | 22.80% | -46.65% | 85.58% |
| Change in Net Operating Assets | -0.01% | -712.29% | -125.65% | 215.05% | -1,324.91% |
| Cash from Operations | 85.89% | -204.51% | -32.50% | 3,734.92% | -45.38% |
| Capital Expenditure | -1.26% | -120.83% | 65.66% | -28.63% | 48.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -100.00% | 0.00% |
| Other Investing Activities | -11.98% | -77.30% | 445.81% | 104.34% | -- |
| Cash from Investing | -3.31% | -725.76% | 111.43% | -221.34% | -132.24% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | 91.20% | -87.51% | -42,346.15% | 84.15% | 98.49% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 93.23% | -96.00% | -40,507.69% | -107.26% | 103.29% |
| Foreign Exchange rate Adjustments | 296.55% | 55.38% | 78.48% | -187.54% | 219.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 84.16% | -3,133.99% | -110.55% | 2,464.22% | 94.61% |